0
Skip to Content
Your Site Title
Home
Pipeline
Our Model
Trials
Partnerships
Foundations
Community
About
CONTACT
Your Site Title
Home
Pipeline
Our Model
Trials
Partnerships
Foundations
Community
About
CONTACT
Home
Pipeline
Our Model
Trials
Partnerships
Foundations
Community
About
CONTACT
Oncoheroes Biosciences 11/11/21 Oncoheroes Biosciences 11/11/21

Oncoheroes Biosciences Inc. Out-licences volasertib to Notable Labs for the Global Adult Development of Its Anticancer Therapy

Read More
Oncoheroes Biosciences 2/15/21 Oncoheroes Biosciences 2/15/21

SHEPHERD Therapeutics and Oncoheroes Biosciences to Partner for the Discovery, Development, and Commercialization of Oncology Therapeutics For Rare Cancers

Read More
Oncoheroes Biosciences 10/14/20 Oncoheroes Biosciences 10/14/20

Volasertib, a potential new treatment for rhabdomyosarcoma, receives Orphan Drug Designation from the U.S. FDA

Read More
Oncoheroes Biosciences 9/24/20 Oncoheroes Biosciences 9/24/20

FDA Grants Rare Pediatric Disease Designation (RPDD) to volasertib for rhabdomyosarcoma

Read More
Oncoheroes Biosciences

Explore

Pipeline Clinical trials White paper

Connect

Partnerships Foundations About Oncoheroes

Boston, Massachusetts

contact@oncoheroes.com
© 2026 Oncoheroes Biosciences, Inc. Privacy Notice